Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Massimo Lombardi,
MRI is the ideal tool for the preoperative evaluation and follow-up of patients with a cardiac tumor. Since it can integrally evaluate signal properties and morphologic characteristics, it allows for the differentiation of benign from malign masses and gives information as to the nature of the mass itself.
Primitive tumors of the heart and of the pericardium are very rare. Of these, approximately 75% are benign and 25% are malignant. In adults the most common benign tumor is the mixoma, in children the rhabdomyoma (40%), and in infants the rhabdomyoma and the theratoma. Of the malignant tumors -more common in adults than in children- 33% are angiosarcomas, 24% rhabdomyosarcomas, 15% mesotheliomias and 10% are fibrosarcomas.
The introduction of MRI in the study of the cardio-vascular apparatus has notably modified the diagnostic strategy of intra-cardiac masses (1-2). Once intracardiac mass is suspected in patients following an echocardiographic study, they are often referred for an MRI evaluation.
This technique provides a complete multiplanar and non-invasive evaluation of the lesions involving the cardiac chambers, pericardium and extracardiac structures, assuming a relevant role in providing diagnostic information useful toward surgical planning. The details to assess are: morphology, dimensions, location, extension, topographic relation, presence of infiltration in the surrounding tissues, and the signal characteristics that can help for a histopatologic characterisation (presence of adipose tissue, necrosis, hemorrhage, calcification, mixoid tissue, vascularisation, etc). In reality, the histopatologic characterisation of lesions is rarely possible except for lipomatose forms (subtraction or suppression of fat). Often, the diagnosis is based on indirect and probabilistic findings, which orientate towards a kind of tumor rather than another.
A correct characterisation of the cardiac and paracardiac mass requires integrated information that is obtainable with the different MRI sequences available. In other words, to characterise a cardiac mass, it is necessary to obtain images in T1, T2, Inversion Recovery or, T1/T2 with spectral suppression of the fat, Gradient Echo T2* (star) (for eventual calcifications or hemorrhages on the inside of the mass), in T1 after paramagnetic contrast medium. Furthermore, it is suggested to obtain images in cine for the study of the movement of the wall involved.
These are generally quite lengthy studies (one hour) which often may bring the physician very close to the nature of the tumor. Table 1 reports the characteristic signals of the various tissue components useful for a diagnostic orientation.
* The type of signal and capture depends on the vascularisation and the cellularity of such tissues (modified by MRI of the Heart and Vessel – M. Lombardi and C. Bartolozzi Eds. 2005, Springer – Verlag – Milan, Berlin)
Hoffmann et Al. (3) have evaluated a cohort of more than 200 cardiac masses and evaluated their signal properties and morphologic characteristics (location, dimension, homogeneity, infiltrative nature, presence of pericardial or pleural effusion, dislocation of surrounding structures) and enhancement of the signal after contrast agent administration. It is noteworthy that no single variable is 100% accurate. On the other hand, in the vast majority of cases, the integration of the above mentioned information allows to reach a highly probable diagnosis. The quality of images, the large view field and the spontaneous contrast between different tissues and different components of the same tissue make MRI the ideal tool in such a pathology. It should be used for the reoperative evaluation and follow-up of patients with a cardiac tumor.
Echocardiography remains the first diagnostic approach when suspecting a cardiac tumor that often appears unexpectedly during an echocardiographic examination. Yet MRI offers several adjunctive advantages which make this technology the most sophisticated among the imaging techniques available today. As the number of centers offering this advanced application of MRI is rapidly growing worldwide, a reasonable and realistic imaging approach should be to conjugate Echocardiography and MRI in the diagnostic process and during follow-up.
Modified from Hoffmann et al. (Am J Cardiol 2003;92:890-895)
Legend of Figure 1 A case of undifferentiated sarcoma. Left panel: presence of a mass infiltrating and expanding within the left atrium (arrows). Right panel: after contrast agent administration it is evident the enhancement of the signal within the tumoral mass (arrows).
1. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, van Rossum AC, Shaw LJ, Yucel EK. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J. 2004 Nov;25(21):1940-65. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15646878&query_hl=2&itool=pubmed_docsum
2. Gerald M. Pohost, MD; Lynne Hung, MD; Mark Doyle, PhD. Clinical Use of Cardiovascular Magnetic Resonance Circulation. 2003;108:647. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12912794&query_hl=5&itool=pubmed_docsum
3. Hoffmann U, Globits S, Schima W, Loewe C, Puig S, Oberhuber G, Frank H. Usefulness of magnetic resonance imaging of cardiac and paracardiac masses. Am J Cardiol. 2003 Oct 1;92(7):890-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14516903&query_hl=7&itool=pubmed_docsum
Dr Massimo Lombardi,
Member of the Nucleus of the WG for Cardiovascular MR of ESC Director MRI Lab Institute of Clinical Physiology C.N.R. Research Campus – Pisa Italy e-mail: email@example.com Tel. +39 050 315 2818 Fax +39 050 315 2166
© 2017 European Society of Cardiology. All rights reserved